Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer

Kaira,Kyoichi; Yanagitani,Noriko; Sunaga,Noriaki; Imai,Hisao; Ono,Akihiro; Koga,Yasuhiko; Hisada,Takeshi; Ishizuka,Tamotsu; Yamada,Masanobu

doi:10.3892/ol.2017.6259

Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer

Authors:
- Kyoichi Kaira
- Noriko Yanagitani
- Noriaki Sunaga
- Hisao Imai
- Akihiro Ono
- Yasuhiko Koga
- Takeshi Hisada
- Tamotsu Ishizuka
- Masanobu Yamada
View Affiliations

Affiliations: Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Gunma University Hospital, Maebashi, Gunma 371‑8511, Japan, Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma University Hospital, Maebashi, Gunma 371‑8511, Japan, Department of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Gunma 373‑8550, Japan, Third Department of Internal Medicine, University of Fukui, Yoshida, Fukui 910‑1193, Japan
Published online on: May 26, 2017 https://doi.org/10.3892/ol.2017.6259
Pages: 1123-1128

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A prospective study was conducted to investigate the efficacy of a combined regimen of gemcitabine and S-1 for the treatment of elderly patients (>70 years) with advanced non‑small cell lung cancer (NSCLC) as a first‑line setting based on the dosage recommended in a previous phase I study. Chemotherapy‑naïve patients with advanced NSCLC received gemcitabine plus S‑1. S‑1 (40 mg/m2) was administered orally twice daily for 14 days while gemcitabine (1,000 mg/m2) was administered on days 1 and 15 of each cycle, and this regimen was repeated every 4 weeks. A total of 20 patients were included in the present study. Of these, 8 patients achieved an overall response rate of 40.0%, and the overall disease control rate was 65.0%. According to the histological type, the response rate in patients with NSCLC and adenocarcinoma was 38.5%, and that for non‑adenocarcinoma was 42.9%. Progression‑free survival and median survival times were 6.4 months and 17.8 months, respectively. Grade 3 or 4 hematological toxicities observed were leukopenia (29%) and neutropenia (24%), while febrile neutropenia was not observed in any patient. The only non‑hematological adverse event observed was grade 3 skin rash (10%). Therefore, the combination of gemcitabine and S‑1 may be a promising and feasible regimen in the first‑line setting for elderly patients with advanced NSCLC.

View Figures

View References

1	Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
2	Chemotherapy in non-small cell lung cancer, . A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 311:899–909. 1995. View Article : Google Scholar : PubMed/NCBI
3	Azzoli CG, Temin S and Giaccone G: 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell. Lung Cancer. J Oncol Pract. 8:63–66. 2012. View Article : Google Scholar : PubMed/NCBI
4	Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, et al: Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomized, phase 3 trial. Lancet. 378:1079–1088. 2011. View Article : Google Scholar : PubMed/NCBI
5	Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H, Yamamoto N, Yoshioka H, Minato K, Sawa T, et al: Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: The intergroup trial JCOG0803/WJOG4307L. J Clin Oncol. 33:575–581. 2015. View Article : Google Scholar : PubMed/NCBI
6	Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
7	Kubota K, Sakai H, Yamamoto N, Kunitoh H, Nakagawa K, Takeda K, Ichinose Y, Saijo N, Ariyoshi Y and Fukuoka M: A multi-institution phase I/II trial of triweeky regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol. 5:702–706. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M and Niitani H: S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: A multi-institutional phase II trial. Clin Cancer Res. 10:7860–7864. 2004. View Article : Google Scholar : PubMed/NCBI
9	Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K and Niitani H; S-1 Cooperative Study Group (Lung Cancer Working Group), : Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 85:939–943. 2001. View Article : Google Scholar : PubMed/NCBI
10	Furuse K, Kawahara M, Hasegawa K, Kudoh S, Takada M, Sugiura T, Ichinose Y, Fukuoka M, Ohashi Y and Niitani H; S-1 Cooperative Study Group (Lung Cancer Working Group), : Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol. 6:236–241. 2001. View Article : Google Scholar : PubMed/NCBI
11	Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, et al: Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: Results of a west Japan oncology group study. J Clin Oncol. 28:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
12	Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, et al: A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol. 26:1401–1408. 2015. View Article : Google Scholar : PubMed/NCBI
13	Guo Zw and Gallo JM: Selective Protection of 2′,2′-Difluorodeoxycytidine (Gemcitabine). J Org Chem. 64:8319–8322. 1999. View Article : Google Scholar : PubMed/NCBI
14	Ichinose Y, Seto T, Semba H, Itoh K, Inoue Y, Tanaka F, Araki J, Tamanoi M, Yamamoto H and Iwamoto N: UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: A multi-institutional phase II trial. Br J Cancer. 93:770–773. 2005. View Article : Google Scholar : PubMed/NCBI
15	Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H and Saisho H: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 94:1575–1579. 2006.PubMed/NCBI
16	Kaira K, Sunaga N, Yanagitani N, Aoki H, Kawata T, Utsugi M, Shimizu Y, Shimizu K, Hisada T, Ishizuka T and Mori M: Phase I trial of oral S-1 plus gemcitabine in elderly patients with non-small cell lung cancer. Anticancer Drugs. 19:289–294. 2008. View Article : Google Scholar : PubMed/NCBI
17	Seto T, Yamanaka T, Wasada I, Seki N, Okamoto H, Ogura T, Shibuya M, Takiguchi Y, Shinkai T, Masuda N, et al: Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502. Lung Cancer. 69:213–217. 2010. View Article : Google Scholar : PubMed/NCBI
18	Satouchi M, Kotani Y, Katakami N, Shimada T, Urata Y, Yoshimura S, Funada Y, Hata A, Ando M and Negoro S: Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer. J Thorac Oncol. 5:696–701. 2010. View Article : Google Scholar : PubMed/NCBI
19	Takiguchi Y, Seto T, Ichinose Y, Nogami N, Shinkai T, Okamoto H, Minato K, Seki N, Eguchi K, Kishi K, et al: Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer. A phase II study. J Thorac Oncol. 6:156–160. 2011. View Article : Google Scholar : PubMed/NCBI
20	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
21	Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
22	Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, et al: Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 24:3657–3663. 2006. View Article : Google Scholar : PubMed/NCBI
23	Gajra A and Jatoi A: Non-small-cell lung cancer in elderly patients: A discussion of treatment options. J Clin Oncol. 32:2562–2569. 2014. View Article : Google Scholar : PubMed/NCBI
24	Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, et al: Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 23:6865–6872. 2005. View Article : Google Scholar : PubMed/NCBI